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Bilirubin is an Endogenous 
Antioxidant in Human Vascular 
Endothelial Cells
Lovro Ziberna1,2, Mitja Martelanc3, Mladen Franko3 & Sabina Passamonti1
Bilirubin is a standard serum biomarker of liver function. Inexplicably, it is inversely correlated with 
cardiovascular disease risk. Given the role of endothelial dysfunction in originating cardiovascular 
diseases, direct analysis of bilirubin in the vascular endothelium would shed light on these relationships. 
Hence, we used high-performance liquid chromatography coupled with thermal lens spectrometric 
detection and diode array detection for the determination of endogenous cellular IXα-bilirubin. To 
confirm the isomer IXα-bilirubin, we used ultra-performance liquid chromatography coupled with a 
high-resolution mass spectrometer using an electrospray ionization source, as well as tandem mass 
spectrometric detection. We measured bilirubin in both arterial and venous rat endothelium (0.9–1.5 
pmol mg−1 protein). In the human endothelial Ea.hy926 cell line, we demonstrated that intracellular 
bilirubin (3–5 pmol mg−1 protein) could be modulated by either extracellular bilirubin uptake, or by 
up-regulation of heme oxygenase-1, a cellular enzyme related to endogenous bilirubin synthesis. 
Moreover, we determined intracellular antioxidant activity by bilirubin, with EC50 = 11.4 ± 0.2 nM, in 
the range of reported values of free serum bilirubin (8.5–13.1 nM). Biliverdin showed similar antioxidant 
properties as bilirubin. We infer from these observations that intra-endothelial bilirubin oscillates, and 
may thus be a dynamic factor of the endothelial function.
Bilirubin is a tetrapyrrole pigment present in various chemical forms in the blood, namely, conjugated 
with glucuronic acid (direct bilirubin), unconjugated bound to serum albumin (indirect bilirubin) and 
unconjugated-unbound (free bilirubin)1. Bilirubin is formed in cells by two sequential reactions, catalysed by 
heme oxygenase (biliverdin-producing, EC 1.14.99.3) and biliverdin reductase (EC 1.3.1.24). Approximately 
250–300 mg bilirubin/day is formed in a normal adult. Most of bilirubin arises in the spleen from the catabolism 
of haemoglobin released form red blood cells. However, the pathway of heme catabolism is active in any kind of 
cells, supporting the turnover of heme, the cofactor of cytochromes and many other enzymes.
Bilirubin has antioxidant and anti-inflammatory activity, and is inversely correlated with disease risk of the 
cardiovascular system, such as ischemic heart disease, hypertension, diabetes type II, metabolic syndrome, and 
obesity, among others2,3. The vascular endothelium that lines the blood vessels plays a fundamental role in cardi-
ovascular disease onset and progression4. Recent studies on the cellular composition of human and mouse tissue 
showed that endothelial cells are the most abundant cells in the heart—about 60 percent – thus implying to have 
an important role in heart physiology and pathology5. However, it is not known if the vascular endothelium is 
the transducer of the ‘bilirubin factor’ put in evidence by the aforementioned epidemiological studies. Therefore, 
the aim of our study was to provide the first ever, direct experimental proof for the presence and bioactivity of 
bilirubin in the vascular endothelium.
Results and Discussion
Is bilirubin an endothelial protective agent? To assess the importance of bilirubin in endothelial 
protection from oxidative stress, we used the standard cell line EA.hy926 as a model of the human vascular 
endothelium. Cells were challenged with an oxidative stress, detected as a time-dependent increase of fluores-
cence emission by an intracellular probe. We assayed the effect of low concentrations of bilirubin (in the nM 
range) for 30 min, finding a concentration-dependent decrease in fluorescence. Data were plotted to quantify 
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the antioxidant effect (Fig. 1) and obtain the EC50. The value found (11.4 ± 0.2 nM) was in the range of reported 
values of free serum bilirubin (8.5–13.1 nM)1. In such a range, the observed system is the most adaptable to 
changes (highest slope). This finding means that small changes in the extracellular bilirubin concentrations can 
be translated into substantially improved intracellular defence against oxidative stress. Biliverdin showed similar 
antioxidant properties as bilirubin, likely due to its conversion to bilirubin by biliverdin reductase6.
Is endothelial bilirubin measurable? Based on these findings, we attempted at analysing intra-cellular 
free bilirubin, by an analytical HPLC method that replaced the standard diode array detector (DAD) detector 
with the ultra-highly sensitive thermal lens spectrometric detection (TLS). The quantification of intracellular bil-
irubin has never been attempted before, due to sensitivity limits of the current analytical methods. Only recently 
has a breakthrough in free bilirubin direct assessment in human and animal serum been accomplished, using a 
hyphenated HPLC-TLS technique1,7. The application of TLS detection instead of DAD has lowered the limits of 
both detection (LOD) and quantification (LOQ) by as much as 20-fold1.
Figure 2 shows the analysis of endogenous bilirubin in endothelial cells, based on MS and MS-MS frag-
mentation patterns, high-resolution mass (presented in Supplementary information), and retention time using 
HPLC-TLS, HPLC-DAD or UPLC-ESI-MS-MS system. Firstly, we used HPLC-TLS, due to its ultra-high sensi-
tivity. Figure 2a shows the HPLC-TLS chromatogram of bilirubin standard solution containing three bilirubin 
isomers (III, IX, XIII-red line) and the endothelial cellular fraction (blue line). Co-elution of both HPLC peaks 
proved the presence of IXα bilirubin in the sample, devoid of unnaturally occurring III and XIII bilirubin iso-
mers. Then, we applied an HPLC-DAD method, which enabled us to successfully perform the peak purity test by 
determining spectral homogeneity across the chromatographic peak, despite the fact that bilirubin concentration 
levels were at the LOQ (see Figure S1 in Supplementary information). The absorbance spectra obtained in both 
the region of eluted peak of standard bilirubin and in the peak present in the sample showed identical absorp-
tion pattern (Fig. 2b). Figure 2c shows UPLC-ESI-MS chromatogram of the endothelial cellular fraction, with 
peaks representing ions with m/z value of 583.3 [M− H+]−. This value was the same as that seen with bilirubin 
standard (Fig. 2d). Figure 2e shows that UPLC-ESI-MS-MS additionally confirms the presence of intracellular 
bilirubin through comparison between the ion fragments pattern in the MS-MS spectra of bilirubin standard and 
the endothelial cellular fraction, both obtained after collision-induced fragmentation of pseudo-molecular ion 
(583.3 [M− H+]−); they showed an identical fragmentation pattern containing a typical bilirubin ion fragment 
corresponding to the m/z value of 285.1.
The detector coupled to the HPLC system, i.e. either one based on TLS or a DAD, determines the performance 
of the methods. The HPLC-DAD method is limited by its sensitivity, which results in higher LOQ (3.5 pmol mg−1 
protein) compared to HPLC-TLS (LOQ = 0.12 pmol mg−1 protein), and consequently in higher measurement 
error and therefore in lower accuracy of the results. For example, the LOQ of HPLC-DAD is about the same as 
changes in intracellular bilirubin levels observed in this study (3–5 pmol mg−1 protein).
In addition to endothelial cell culture experiments (EA.hy926 cells), we confirmed the presence of endoge-
nous bilirubin in the endothelium isolated from both rat aorta and vena cava inferior. The values obtained were 
1.53 ± 0.57 and 0.93 ± 0.14 pmol bilirubin mg−1 proteins (means ± SEM, n = 3), respectively.
Is endothelial bilirubin dynamically regulated? The remarkable gain in sensitivity offered by com-
bining HPLC with TLS detection enabled to address the question whether the vascular endothelium is a 
bilirubin-accessible compartment. Many clinical studies have shown the potential to modulate serum biliru-
bin values by either lifestyle modifications or pharmacological interventions targeting bilirubin transporters 
and enzymes, e.g. biliverdin reductase, heme oxygenase, UDP-glucuronosyltransferase (UGT1A1), organic 
anion-transporting polypeptide (OATP), and others. In turn, these changes can have an impact on individual 
cardiovascular disease risk8, as well as can be used as an early biomarker for the development of metabolic syn-
drome9. However, it is so far unanswered if bilirubin contents in the vascular endothelium can be modulated, 
which could result in a different capacity to withstand oxidative stress and limit cellular structural damage.
Figure 1. Endothelial cellular antioxidant activity (CAA) of bilirubin, and its synthetic precursor 
biliverdin. Endothelial cells (Ea.hy926) were exposed to different concentrations of bilirubin or biliverdin (0.5, 
2, 5, 10, 25, 50, 75 and 100 nM) in the albumin-free cell medium for a period of 30 min before the start of CAA 
assay. Results are expressed as means ± SEM from hexaplicates of 3 independent experiments.
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Thus, we designed two experiments aimed to assess dynamic changes in cellular bilirubin levels. In the first 
one, EA.hy926 cells were treated with 10 μ M CoPPIX for 24 hours to induce the enzyme heme oxygenase-1 and 
thus increase cellular bilirubin synthesis. In the second one, the cells were kept in albumin-free cell media supple-
mented with 50 nM bilirubin for 30 min. The HPLC-TLS method enabled to measure increased intracellular bili-
rubin in both cases. Specifically, it was 3.14 ± 0.17, 4.34 ± 0.26 and 5.24 ± 0.51 pmol mg−1 protein (means ± SEM 
from triplicates of 6 independent experiments) under control conditions, heme oxygenase induction (P > 0.05) 
and bilirubin supplementation (P > 0.001), respectively. Though other technologies are needed to study the exact 
localization of bilirubin in the cells, it can be guessed that bilirubin can be present in: i) the cytosol, as either free 
or bound to intracellular proteins (e.g. glutathione-S-transferase A, previously known as ligandin); ii) cell mem-
branes or iii) intracellular membrane compartments, due to its lipophilic character10. Whatever the case may be, 
these data corroborate the concentration-dependent antioxidant activity of bilirubin (shown in Fig. 1), either as a 
lipid peroxidation inhibitor or as a radical scavenger11,12.
Conclusions
Our data explain why increased HO-1 expression level can lead to improved disease outcomes13. Moreover, 
this study enables to conclude that the protection against cardiovascular disease risk afforded by familial 
Figure 2. Bilirubin determination in endothelial cells. Endogenous bilirubin in endothelial cells (Ea.hy926) 
was identified by HPLC-TLS, HPLC-DAD or UPLC-ESI-MS-MS system. (a) HPLC-TLS chromatogram of 
bilirubin standard solution containing the three bilirubin isomers (III, IX, XIII - red line) and the endothelial 
cellular fraction (blue line). (b) HPLC-DAD chromatograms of bilirubin standard (10 nM, red line) and 
endothelial cellular fraction (blue line). (c) UPLC-ESI-MS chromatogram of analysed endothelial cellular 
fraction with peaks representing ions with m/z value of 583.3 [M− H+]−. (d) MS spectrum containing ion with 
m/z value of 583.3 [M− H+]− obtained after UPLC-ESI-MS analyses at retention time of bilirubin standard 
elution. (e) MS-MS spectrum containing ion with m/z value of 285.1 after UPLC-ESI-MS-MS of bilirubin 
standard and the sample of endothelial cellular fraction.
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hyperbilirubinemia (Gilbert’s syndrome)14 is indeed mediated by an increased availability of the intracellular 
biliverdin/bilirubin redox pair, which improves the performance of the vascular endothelium in buffering reactive 
oxygen and nitrogen species15.
Given its anatomical size (ca. 240 m2 in a human subject)16, the contribution of the vascular endothelium to 
the physiological redox homeostasis is most prominent.
Materials and Methods
Chemicals. Methanol and anhydrous dimethyl sulfoxide (DMSO), both HPLC grade, were obtained from 
Merck (Darmstadt, Germany). Fetal bovine serum (FBS), L-glutamine and penicillin-streptomycin solution 
were obtained from EuroClone (Milano, Italy); and 2′ ,7′ -dichlorofluorescin diacetate (DCFH-DA), 2,2′ -azobis 
(2-amidinopropane) dihydrochloride (ABAP), cobalt-protoporphyrin IX (CoPPIX), bilirubin, and biliverdin 
were purchased from Sigma-Aldrich (Steinheim, Germany).
Phosphate Saline buffer (PBS): 200 mg/L KCl (Merck, Darmstadt, Germany); 200 mg/L KH2PO4 (Carlo Erba, 
Milano, Italy); 8000 mg/L NaCl; 1150 mg/L Na2HPO4 (Carlo Erba, Milan, Italy). Hank’s buffered saline solution 
(HBSS): 185 mg/L CaCl2 × 2H2O; 60 mg/L KH2PO4; 350 mg/L NaHCO3; 8000 mg/L NaCl; 47.88 mg/L Na2HPO4 
(Carlo Erba, Milano, Italy); 100 mg/L MgCl2 × 6H2O; 1000 mg/L glucose (Sigma-Aldrich, Steinheim, Germany); 
100 mg/L MgSO4 × 7H2O; 400 mg/L KCl (Merck, Darmstadt, Germany); the pH was adjusted to 7.4 using 0.1% 
HCl (Merck, Darmstadt, Germany). Ultrapure Milli-Q water (Merck Millipore, Billerica, MA) was used for the 
preparation of the solutions.
Bilirubin solutions. Bilirubin stock solution (5 mM) was prepared in DMSO. Then, it was diluted to 100 μ M 
in 10 mM NaOH aqueous solution. Further diluted solutions were prepared using PBS. All dilutions were done in 
a dark room to avoid bilirubin photodegradation.
Cell culture. Human endothelial cell line Ea.hy926 (American Type Culture Collection, Rockville, USA) 
was grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum, 1 mM 
L-glutamine and 1 mM penicillin-streptomycin solution. Cells were grown in an incubator at 37 °C in a humidi-
fied atmosphere (95% air and 5% of carbon dioxide).
Cellular antioxidant activity assay. Endothelial cells EA.hy926 were seeded on 96-well plates (104 cells/well), 
containing 100 μ L of complete DMEM/well and grown for 24 hours. Then, the cells were washed twice with 
PBS, and incubated for 30 minutes with bilirubin or biliverdin, dissolved in 100 μ L MGD solution (incomplete 
albumin-free DMEM, 1 mM L-glutamine, 50 μ M DCFH-DA) at the following concentrations: 0 (control), 0.5, 2, 5, 
10, 25, 50, 75 and 100 nM. After incubation, the solution was removed and the cells were washed twice with PBS. 
Then, the cells were treated with the peroxyl radical-generating reagent ABAP, at 5 mM in 100 μ L Hank’s buffered 
saline solution (HBSS). The blank wells were filled with HBSS solution without ABAP. The fluorescence was meas-
ured at 535 nm with excitation at 485 nm every 5 min for one hour at 37 °C on a microplate reader (Synergy™ H1, 
Bio-Tek Instruments, Winooski, VT, USA). To quantify the cellular antioxidant activity, the CAA units (%) were 
calculated as follows:
∫ ∫= − ×( )SACAA units (%) 100 CA 100
where ∫ SA is the integrated area under the sample fluorescence readings (with the blank subtracted) versus the 
time curve, and ∫ CA is the integrated area under the control curve.
Bilirubin uptake study. Endothelial cells (Ea.hy926) were grown in flasks (75 cm2) in completed DMEM for 
48 hours to reach confluence. Monolayers were washed with PBS twice. Then, 500 μ L of 50 nM bilirubin solution 
(dissolved in PBS) were added for 30 minutes. All experiments were performed in the dark room.
Heme oxygenase-1 (HO-1) induction. Endothelial cells (Ea.hy926) were grown in flasks (75 cm2) in 
completed DMEM for 24 hours. Then, they were incubated in CoPPIX solution (10 μ M) dissolved in fresh com-
pleted DMEM for 24 hours before harvesting. CoPPIX is widely applied as a HO-1 inducer in various experimen-
tal models, especially in vitro cellular studies, where 3 μ M CoPPIX induced maximal level of HO-1 expression at 
18 hours of incubation6.
Cell harvesting and sample preparation. Cells were washed with PBS twice, scraped in 500 μ L of MeOH: 
DMSO (1:1, v/v) and collected into an Eppendorf vial. This protocol was repeated twice. The pooled harvest 
was ultrasonified for 1 min in an ice bath, rewarmed to room temperature and centrifuged at 12.000 rpm. To 
determine total protein concentration in the sample, we used Bradford assay on 20 μ L of supernatant. The rest of 
supernatant was diluted with deionized water (1:1, v/v) to make the final sample prior to HPLC-TLS, HPLC-DAD 
or HPLC-ESI-MS analysis. In order to improve signal-to-noise ratio due to bilirubin’s low ionization efficiency 
and its low concentration in the 10 mL-injection loop of the UPLC system, some samples were concentrated by 
liquid-liquid extraction using chloroform (0.5 mL) prior to mass spectrometric analysis. The bottom chloroform 
phase was decanted to a new Eppendorf vial and the solvent was removed by a stream of nitrogen gas. The residue 
was redissolved in DMSO:H2O (1:1, v/v) to obtain a final volume of 300 μ L (concentrated bilirubin solution).
Bilirubin analysis in cell samples. All mass spectrometry data were obtained by Waters Acquity 
ultra-performance liquid chromatograph (UPLC, Waters Corp., Milford, MA, USA) using the flow rate of 0.7 mL/min, 
the injection volume of 10 μ L and the BEH C18 column (1,7 μ m, 50 × 2,1 mm i.d.). Other chromatographic conditions 
for HPLC-TLS method were as previously published1.
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The LC system was coupled to a hybrid quadrupole orthogonal acceleration time-of-flight mass spectrome-
ter (Q-ToF Premier, Waters, Milford, MA, USA); analyses were made in negative ion mode using electrospray 
chemical ionization (ESI). The capillary voltage was 3.0 kV, while the sampling cone voltage was 20 V. The source 
and desolvation temperatures were 130 °C and 400 °C, respectively. The flow rate of nitrogen desolvation gas 
was 500 L/h. The acquisition range was between m/z 50 and m/z 1000 with argon serving as a collision gas at a 
pressure of 4.5 × 10−3 mbar in the T-wave collision cell. The tandem mass spectrometric analysis (MS-MS) was 
performed using collision energies from 15 to 30 eV to generate the product ion spectra that provided the best 
structural information. The data were collected in centroid mode, with a scan accumulation time of 0.2 s and an 
interscan delay of 0.025 s. The data station utilized the MassLynx v4.1 operating software. Accurate mass meas-
urements (Supplementary Information Figure S2) were obtained with an electrospray dual sprayer using the ref-
erence compound leucine enkephalin ([M + H+]+ = 556.2271) at a high mass resolution of approximately 10000 
full width of the peak at half its maximum height (FWHM) UPLC-MS spectrum in the Fig. 2c was obtained after 
a sample (from the control group) 5-fold pre-concentration (by solvent evaporation under reduced pressure), 
thus in the 3–6 min time range some peaks appear due to bilirubin degradation during sample concentration. 
Sample concentration prior analysis was needed, since the bilirubin signal intensity (m/z of 583,2) in the analysed 
sample (from the control group) was almost insignificant (under LOD), as shown in Supplementary Information 
(Figure S3).
Limit of detection (LOD) and limit of quantification (LOQ) were determined using the peak representing bli-
rubin based on a visual determination of a peak-to-peak signal-to-noise ratio of at least 3:1 and 10:1, respectively.
Animals. Adult male Wistar rats weighing 330–350 g (5 months of age) were housed under standard labora-
tory conditions in a temperature-controlled environment (22 ± 1 °C, 60% humidity) maintained on a 12-h light/
dark cycle. All animal procedures and study protocols were approved and conducted in accordance with the 
permission issued by the Veterinary Administration of the Republic of Slovenia (permit SI-No. U34401-4/2014/4, 
given to Institute of Pharmacology, Faculty of Medicine, University of Ljubljana), which conforms with the Guide 
for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996).
Blood vessel isolation. Three rats were killed by cervical dislocation and bled. From each animal both 
aorta and vena cava inferior were dissected from the thorax, cleaned of connective tissue and periadventitial fat. 
To remove any remaining blood, blood vessels were rinsed with cold PBS three times (by using a syringe), and 
were left for additional 5 minutes in the 50 mL beaker filled with the cold PBS solution under dark conditions. 
To expose the complete endothelium surface, all blood vessels were carefully opened by a longitudinal cut. The 
endothelial cells were gathered by gentle abrasion with a clean scalpel blade from the edges to the center of the 
blood vessel. Detached cells were immediately collected in 100 μ L of MeOH: DMSO (1:1, v/v) into an Eppendorf 
vial. The pooled harvest was ultrasonified for 1 min in an ice bath, rewarmed to room temperature and centri-
fuged at 12.000 rpm. To determine total protein concentration in the sample, we used Bradford assay on 20 μ L of 
supernatant. The rest of supernatant was diluted with deionized water (1:1, v/v) to make the final sample prior to 
HPLC-TLS.
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